These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7872083)

  • 1. Urokinase and its receptor: marker of malignancy?
    Gaffney PJ; Cooke DA; Burnand KG
    Adv Exp Med Biol; 1994; 360():187-91. PubMed ID: 7872083
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
    Ho CH; Chao Y; Lee SD; Chau WK; Wu CW; Liu SM
    Thromb Res; 1998 Jul; 91(1):23-7. PubMed ID: 9700849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion.
    Ellis V; Pyke C; Eriksen J; Solberg H; Danø K
    Ann N Y Acad Sci; 1992 Dec; 667():13-31. PubMed ID: 1339241
    [No Abstract]   [Full Text] [Related]  

  • 4. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
    Chucholowski N; Schmitt M; Goretzki L; Schüren E; Moniwa N; Weidle U; Kramer M; Wagner B; Jänicke F; Graeff H
    Biochem Soc Trans; 1992 Feb; 20(1):208-16. PubMed ID: 1321752
    [No Abstract]   [Full Text] [Related]  

  • 6. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.
    Duffy MJ; O'Grady P; Devaney D; O'Siorain L; Fennelly JJ; Lijnen HJ
    Cancer; 1988 Aug; 62(3):531-3. PubMed ID: 3134120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
    Jankun J; Merrick HW; Goldblatt PJ
    J Cell Biochem; 1993 Oct; 53(2):135-44. PubMed ID: 8227186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
    Tang L; Han X
    Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activator and its receptor in bladder cancer.
    Hasui Y; Osada Y
    J Natl Cancer Inst; 1997 May; 89(10):678-9. PubMed ID: 9168177
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor.
    Albo D; Rothman VL; Roberts DD; Tuszynski GP
    Br J Cancer; 2000 Aug; 83(3):298-306. PubMed ID: 10917542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
    Hasui Y; Osada Y
    J Natl Cancer Inst; 1997 Nov; 89(21):1630-1. PubMed ID: 9362166
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: urokinase and urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
    Duffy MJ; Duggan C
    J Natl Cancer Inst; 1997 Nov; 89(21):1628-30. PubMed ID: 9362165
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta.
    Nishida Y; Hayashi Y; Imai Y; Itoh H
    Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
    Hudson MA; McReynolds LM
    J Natl Cancer Inst; 1997 May; 89(10):709-17. PubMed ID: 9168186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins.
    Ranson M; Andronicos NM; O'Mullane MJ; Baker MS
    Br J Cancer; 1998 May; 77(10):1586-97. PubMed ID: 9635833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.